387 million people globally were living with diabetes in 2014.


Diabetes is considered to be the third millennium disease, affecting 10% of the World’s population


One in two people with diabetes DO NOT KNOW they have it.


Every 7 seconds one person dies from diabetes.

Diabetes is considered to be the third millennium disease, affecting 10% of the world’s population. According to the IDF Diabetes Atlas, sixth edition, of the International Diabetes Federation 2014, 387 million people globally were living with diabetes in 2014. This number will increase to 592 million globally by 2035, a shocking 55% increase!


Living with diabetes is difficult for the patient and their families. There are grave economic consequences for the family and ultimately for the country where there are high concentrations of diabetic sufferers. Despite these concerning statistics, the cosmeceutical market offers very few products for the care and prevention of diabetes-related issues [Cosmeceuticals are cosmetics with active biological ingredients].

Education is a key-value in understanding and living with diabetes. The International Diabetes Federation has published a very informative video to demonstrate a basic understanding of this increasing global dilemma. The Apoema® Diabetes Pro Care product line has been designed to assist pre-diabetic and diabetic patients to control some of the issues patients suffer under.  This product line is designed to educate people to prevent diabetic issues.

Apoema® is pleased to share this academic video with you. Please select your preferred language to watch this educational movie by selecting the play button on a flag of your choice.

United-Kingdom-flag Saudi-Arabia-Flag  Brazil-Flag  Spain-Flag-icon  France-Flag 

The International Diabetes Federation has designed a powerful tool for advocacy on behalf of people suffering under diabetes and these Scorecards highlight areas of good practice and identify areas for more effective action. The following Scorecards show much has to be done and the Apoema® Premium Cosmeceuticals can assist in providing a great social impact and reduced Government spending.


Saudi Arabia Argentina Brazil
Canada Germany Egypt
India Iran Sudan
United Kingdom USA Jordan

Diabetic Retinopathy and Braille

Diabetic retinopathy, also known as diabetic eye disease, is when damage occurs to the retina due to diabetes. It is an ocular affirmation of diabetes, a systemic disease, which affects up to 80 percent of all patients who have had diabetes for 10 years or more.

Approximately one-third of diabetic people develop some degree of diabetes-related eye damage, or retinopathy. This complication, which is characterised by damage to the retina provoked by microvascular changes resulting from diabetes, can lead to partial vision loss and more often than not to blindness.

Around 10% of patients diagnosed with diabetes suffer from severe visual impairment. On a global scale this translates to millions of people!

Blind diabetics and those losing their vision have to continue to live independently. Apoema® has opted to assist blind diabetics by printing Braille on the primary packaging of its Diabetes Pro Care product line. Braille is the internationally widespread reading and writing system for blind and partially sighted people.

While the European Union has issued directives to print Braille on nutraceutical and pharmaceutical labels, no such directive exists for cosmetics or cosmeceuticals within the European Union or any other country in the World.

Apoema®, however, strongly opines that blind diabetics and diabetic patients with impaired vision deserve correlative independence with cosmeceutical products and for that principle Apoema® is a vanguard to this initiative.

Social Impact

The World Economic Forum

The World Economic Forum in Davos, Switzerland, has described Diabetes as one of the scourges of modern society, and the number of cases is rising every year. Already, there are over 380 million diabetic patients around the world. The International Diabetes Foundation estimates that by 2030, over half a billion people will be suffering from type 2 diabetes.

The Cost of Diabetes in the United States of America

The Diabetes dilemma in the United States is an unfortunate showcase.

The American Diabetes Association released new research on March 6, 2013, which data was confirmed by the USA Centers for Disease Control “National Diabetes Statistics report” in 2014, estimating that the total costs of diagnosed diabetes have risen to US$245 billion annually and addresses the increased financial burden, health resources used and lost productivity associated with this diabetes epidemic.

The largest components of medical expenditures are:

  • hospital inpatient care (43% of the total medical cost),
  • prescription medications to treat complications of diabetes (18%),
  • anti-diabetic agents and diabetes supplies (12%),
  • physician office visits (9%), and
  • nursing/residential facility stays (8%)

And it does not stop here, because of the enormous indirect costs:

  • increased absenteeism (US$5 billion) and
  • reduced productivity while at work (US$20.8 billion) for the employed population,
  • reduced productivity for those not in the labor force (US$2.7 billion),
  • inability to work as a result of disease-related disability (US$21.6 billion), and
  • lost productive capacity due to early mortality (US$18.5 billion).

These figures represent the costs in the United States of America and similar or even higher percentages of diabetes prevalence and cost of treatment can be found in the vast majority of countries around the globe, especially in countries with a very high prevalence of diabetes like the GCC countries in the Middle East (the GCC consists of the Kingdom of Bahrain, Kuwait, the Sultanate of Oman, Qatar, the Kingdom of Saudi Arabia, and the United Arab Emirates).

Accumulating Economic Burden

Diabetes has become a development issue. It threatens health and economic prosperity. For example, the GCC diabetes prevalence rate has jumped to between 18% – 25% due to the expansive socio-economic development in a relatively short period of time.

People with diabetes must pay for their care out of their own pocket because public medical services and insurance are lacking.

Some country examples of annual spending:
Region/Country Total Spending Health Care Total Spending Diabetes
USA US$ 3.25 trillion US$ 245.0 billion
UAE US$ 20 billion US$ 2.4 billion

Governments are reeling under the anticipated new waves of costs that will inevitably come unless there is more widespread, proactive treatment and education. For example, as recently stated by the Middle East Regional Chair of the International Diabetes Federation, Dr. El Sayed, when noting that Dubai is scheduled to increase diabetes related spending from US$16.86 billion in 2014 to US$24.76 billion in 2035:

    • The diagnosis of diabetes in a low or middle-income country can often drag entire families into poverty.
    • The world needs to invest in integrated health systems that can diagnose, treat, manage and prevent diabetes.
    • Governments need to invest in actions outside the formal health sector, particularly in promoting healthier diets and physical activity, to reduce obesity and the risk of type 2 diabetes. Without effective prevention diabetes will overwhelm health systems and hinder economic growth.
    • The epidemic represents nothing short of a global health emergency.
    • It is alarming that world leaders stand by while the diabetes fuse slowly burns. The serious impact on families, countries and economies continues with little resistance. Governments must take action to defuse the threat now, before the diabetes time bomb explodes.
    • That heavy burden underscores the urgent need for increased investments in the prevention and management of diabetes. In particular, governments need to provide long term tax incentives and attractive financing to encourage private investment in research & development for new diabetes products that are readily available to the entire population and treat diabetes early on. Greater emphasis should be placed on topical and dental applications with affordable cost so these products can be utilized several times daily and hold the promise that the patient may avoid costly long term care facilities and the accompanying loss of income and productivity.

Aggressive Preventive Apoema® Pro Care Management

Literally billions of U.S. Dollars and tens of thousands of lives can be saved with aggressive management and treatment of diabetes.

The Apoema® Pro Care Diabetes topical and oral products line as well as high quality new Apoema® Pro Care Diabetes cosmeceutical products that are currently under development provide strong and cost-efficient management techniques that can reduce, and in some cases prevent, long term in-patient care that often leads to death.

These management techniques also result in significant increases in work force productivity that ultimately provide the government authorities with huge savings in both long term care and related infrastructure spending. The result would be decreased pressure on medical and nursing staffs and family environments that have to take care of their diabetic family members.

© Copyright IAH Comércio de Cosméticos Ltda — By Mezcla Design
Translate »